Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 3/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 3/20 | 0.53 |
| ▸ | BRAF | P15056 | 11/20 | 0.49 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367427 | 0.91 | KIT (0.56) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL4114192 | 0.90 | PIK3CA (0.55) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL1366062 | 0.86 | BRAF (0.62) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL17420246 | 0.85 | NPC1 (0.55) | KITPIK3CAMTORBRAF | |
| SCHEMBL1367204 | 0.85 | KIT (0.50) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL1367703 | 0.85 | PIK3CA (0.60) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL4120001 | 0.83 | EPHX2 (0.46) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL4113859 | 0.82 | KIT (0.56) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL4503280 | 0.82 | P4HTM (0.52) | KITPIK3CAMTORBRAFABL1 | |
| SCHEMBL1368423 | 0.81 | KIT (0.53) | KITPIK3CAMTORBRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067599-B2 | Imidazo [4,5-B] pyridine and pyrrolo [2,3-B] pyridine protein kinase inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| EP-2064213-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008028617-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318428-A1 | HETEROARYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K5, MAP3K1, PRKACA | KIT 1200/4885PIK3CA 155/4885MTOR 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.